Of the top 21 most common types of cancer in the UK, pancreatic has the lowest survival rate – with just 4 percent of patients surviving five years or more – a figure which hasn’t changed in more than 40 years – and more than 200,000 people around the world die from pancreatic cancer annually.
A key challenge is the late stage at which pancreatic cancer is often diagnosed, when the risk associated with surgery and conventional chemotherapy are very high. By enabling targeted therapy with minimal side effects, SonoTarg offers a potential alternative that could significantly improve the outcome for pancreatic cancer patients.